Videos

Tony Mok, MD, discusses the next steps for pembrolizumab (Keytruda) as a treatment option for patients with non-small cell lung cancer after the phase III KEYNOTE-042 trial.

Alexander E. Perl, MD, discusses the latest advancements in the treatment landscape for patients with acute myeloid leukemia. These advances are driven by 2 factors: a better understanding of the biology of the disease and improving therapeutics to meet that understanding.

Bladder Cancer

Relapse After Second-Line Therapy in Follicular Lymphoma

Ryan J. Sullivan, MD, discusses the role of checkpoint inhibitors in the treatment landscape for patients with melanoma.

Elias Jabbour, MD, discusses the latest advancements in the treatment landscape for acute lymphocytic leukemia that are moving the paradigm away from chemotherapy.

Case Review: Progression in Follicular Lymphoma

Thomas W. Flaig, MD, discusses the most dramatic change in the treatment landscape for patients with advanced bladder cancer. Over the last several years, 5 checkpoint inhibitors have been approved in this space.

John H. Ward, MD, discusses the role of 21-gene assays in selecting patients with breast cancer for adjuvant chemotherapy treatment.

Carla Casulo, MD, discusses the challenges surrounding the treatment of patients with relapsed/refractory follicular lymphoma.